CHMP recommends extending use of Nexavar in Thyroid Cancer-Bayer HealthCare
The EMA's CHMP has recommended extending the use of the cancer medicine Nexavar (sorafenib), from Bayer HealthCare, to the treatment of progressive, locally advanced or metastatic, differentiated Thyroid Cancer. Current treatment options for thyroid cancer include radioactive iodine and surgery as well as therapy to suppress thyroid-stimulating hormone (TSH).
The CHMP has recommended the approval of Nexavar for use in patients who no longer respond to treatment with radioactive iodine. Although chemotherapy with doxorubicin is authorised in some EU Member States for treatment of these patients, there is currently no generally recommended treatment option for this group, who therefore represent an unmet medical need.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.